Tuis8AP • FRA
add
Agios Pharmaceuticals Inc
Vorige sluiting
€25,00
Dagwisseling
€25,00 - €25,00
Jaarwisseling
€19,70 - €38,80
Markkapitalisasie
1,77 mjd USD
Gemiddelde volume
3,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 19,97 m | 86,09% |
Bedryfskoste | 51,61 m | -0,17% |
Netto inkomste | -108,04 m | -11,93% |
Netto winsgrens | -541,09 | 39,85% |
Wins per aandeel | -1,85 | -6,32% |
EBITDA | -120,31 m | 2,72% |
Effektiewe belastingkoers | 0,93% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 854,42 m | -4,40% |
Totale bates | 1,30 mjd | -22,00% |
Totale aanspreeklikheid | 104,11 m | -14,83% |
Totale ekwiteit | 1,19 mjd | — |
Uitstaande aandele | 58,59 m | — |
Prys om te bespreek | 1,22 | — |
Opbrengs op bates | -22,66% | — |
Opbrengs op kapitaal | -23,73% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -108,04 m | -11,93% |
Kontant van bedrywe | -96,21 m | 27,75% |
Kontant van beleggings | 90,08 m | 283,24% |
Kontant van finansiering | 2,56 m | -47,19% |
Netto kontantverandering | -3,58 m | 97,98% |
Beskikbare kontantvloei | -62,05 m | 42,58% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
540
